Gilead Sciences (GILD) is a publicly traded Healthcare sector company. As of May 20, 2026, GILD trades at $130.37 with a market cap of $160.99B and a P/E ratio of 17.61. GILD moved +0.10% today. Year to date, GILD is +7.32%; over the trailing twelve months it is +22.93%. Its 52-week range spans $81.83 to $157.29. Analyst consensus is strong buy with an average price target of $159.83. Rallies surfaces GILD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
GILD financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. GILD recently traded at $130.37. Market cap is $160.99B. P/E ratio is 17.61. Revenue is $29.74B.
| Metric | Value |
|---|---|
| Price | $130.37 |
| Market Cap | $160.99B |
| P/E Ratio | 17.61 |
| EPS | $7.42 |
| Dividend Yield | 0.82% |
| 52-Week High | $157.29 |
| 52-Week Low | $81.83 |
| Volume | 3.70M |
| Avg Volume | 0 |
| Revenue (TTM) | $29.74B |
| Net Income | $9.22B |
| Gross Margin | 79.36% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $29.44B | $8.51B | $6.84 |
| 2024 | $28.75B | $480.00M | $0.38 |
| 2023 | $27.12B | $5.61B | $4.54 |
| 2022 | $27.28B | $4.57B | $3.66 |
22 analysts cover GILD: 0 strong buy, 18 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $159.83.